Robotic PCI and Protection from Occupational Hazards Highlighted During "21st Century Solutions to the Current Cath Lab Challenges: UC San Diego Approach" on May 7

WALTHAM, Mass.--(BUSINESS WIRE)--

Corindus Vascular Robotics, Inc. CVRS, a leading developer of precision vascular robotics, will sponsor a dinner event during the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego, California. The dinner event, "21^st Century Solutions to the Current Cath Lab Challenges: UC San Diego Approach," will take place on Thursday, May 7, from 7 – 9 p.m. at the UC San Diego (UCSD) Medical Center, and will feature Dr. Ehtisham Mahmud, Chief of Cardiovascular Medicine, Director of Sulpizio Cardiovascular Center at UCSD, who will discuss cath lab economics of simple and complex PCI.

Attendees of the dinner event will also hear from Anthony DeMaria, MD, MACC, Professor of Medicine, Founding Director, Sulpizio Cardiovascular Center, University of California, San Diego about his view on the "Future of Cardiology;" Manos Brilikas, MD, Director, VAMC Catheterization Lab, UT Southwestern, about the hazards of working in the cath lab; and Giora Weisz, MD, FACC, FSCAI, Chairman, Department of Cardiology, Shaare Zedek Medical Center about the benefits of robotic-assisted PCI.

Dinner guests will also have the opportunity to tour the UC San Diego Medical Center's catheterization lab and see how robotics can be applied to complex PCI within the lab's daily workflow. In addition to allowing cardiologists to advance stents and guidewires millimeter-by-millimeter using digital controls, the CorPath System enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure.

In addition to sponsoring the dinner event, Corindus will showcase its technology in booth #313 at SCAI 2015. Attendees are invited to perform a CorPath robotic-assisted PCI using a virtual reality simulator in the booth.

To register for the dinner event, visit www.scai.org/SCAI2015CathLabTour. To schedule a hands-on demonstration of robotic–assisted PCI with the CorPath System, visit the Corindus website.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's FDA-cleared CorPath 200 System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help physicians potentially provide better clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this press release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus' financial results is included from time to time in the "Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus' periodic and current filings with the SEC, as well as those discussed under the "Risk Factors" and "Forward-Looking Statements" section of Corindus' Annual Report on Form 10-K filed with the SEC on March 30, 2015, and available on Corindus' website at http://www.corindus.com/about-corindus/investor-relations. Forward-looking statements speak only as of the date they are made and Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, that occur after that date.